Innate Pharma: Moving Into The Padcev Space
Source: SeekingAlpha
2025-03-21 09:10:35 ET
Summary
- Innate Pharma's diverse pipeline, including lacutamab, IPH6501, and IPH4502, shows promising clinical activity and potential for significant milestones in 2025.
- Lacutamab, a key asset, received US FDA Breakthrough Therapy designation, enhancing its development prospects and partnership potential.
- Financially, IPHA has a cash runway until the end of 2025, but may face a cash crunch, likely requiring equity raises or partnerships, in my opinion.
- Despite risks, including potential dilution and high development costs, I remain optimistic and maintain a "Buy" rating for IPHA.
Topline Summary and Update
Read the full article on Seeking Alpha
For further details see:
Innate Pharma: Moving Into The Padcev Space
Innate Pharma S.A.
NASDAQ: IPHA
IPHA Trading
-2.88% G/L:
$1.6608 Last:
16,817 Volume:
$1.69 Open:
IPHA Latest News
April 13, 2026 01:00:00 am
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026April 08, 2026 01:00:00 am
Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering EventIPHA Stock Data
$162,196,580
59,035,869
N/A
7
N/A
Biotechnology & Life Sciences
Healthcare
FR
Marseille
